Buy Glenmark Pharma: Kunal Saraogi

Kunal Saraogi, CEO of Equityrush told CNBC-TV18, "Glenmark Pharma has been consolidating and it’s been consolidating in a very narrow range. I see a breakout from that range in today’s trade. The stock is up above two percent and I see it going further up."

"Pharma is back in favor, we have seen big corrections in almost every pharma stock. However, now that they have corrected quite substantially, I think they might resume their uptrend. Glenmark can get to Rs 760 levels if one were to hold it long enough but at current levels definitely it is a buy," he said.